XENCOR
Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.
XENCOR
Industry:
Biotechnology Health Care Therapeutics
Founded:
1997-01-01
Address:
Monrovia, California, United States
Country:
United States
Website Url:
http://www.xencor.com
Total Employee:
51+
Status:
Active
Contact:
626-305-5900
Total Funding:
133.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API WordPress Domain Not Resolving Wordpress Plugins Mobile Non Scaleable Content Sitelinks Search Box
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Applied Molecular Transport
Applied Molecular Transport developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases.
Cerulean Pharma
Cerulean Pharma develops nanotechnology-based therapeutics for treating oncology, cardiovascular, autoimmune and inflammatory diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Kinnate Biopharma
Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Nimbus Therapeutics
Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Vetigenics
Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Zebra Biologics
Zebra Biologics develops bio superior agonist and antagonist antibody therapeutics for many diseases.
Current Advisors List
Board_member
Board_member
2015-07-01
Board_member
2019-01-01
Current Employees Featured
David Szymkowski Vice President, Cell Biology @ Xencor
Vice President, Cell Biology
2002-01-01
John Kuch Senior Vice President & Chief Scientific Officer @ Xencor
Senior Vice President & Chief Scientific Officer
Bassil Dahiyat Founder, President & CEO @ Xencor
Founder, President & CEO
1997-01-01
Edgardo Baracchini Chief Business Officer @ Xencor
Chief Business Officer
John Desjarlais Vice President, Research @ Xencor
Vice President, Research
2006-01-01
John Desjarlais Chief Scientific Officer @ Xencor
Chief Scientific Officer
2014-07-01
Founder
Stock Details
Investors List
Oxford Bioscience Partners
Oxford Bioscience Partners investment in Series E - Xencor
Novo Nordisk
Novo Nordisk investment in Series E - Xencor
Merlin Nexus
Merlin Nexus investment in Series E - Xencor
Zen Investments
Zen Investments investment in Series D - Xencor
Moore Capital
Moore Capital investment in Series C - Xencor
Sands Brothers Asset Management
Sands Brothers Asset Management investment in Series C - Xencor
Stafford Capital Partners
Stafford Capital Partners investment in Series C - Xencor
Stafford Capital Partners
Stafford Capital Partners investment in Series B - Xencor
Official Site Inspections
http://www.xencor.com Semrush global rank: 1.74 M Semrush visits lastest month: 13.58 K
Unable to get host informations!!!
More informations about "Xencor"
About Us - Xencor
Before Xencor, Mr. Cornelissen was vice president, corporate finance at Seagen Inc., where he built and scaled the corporate finance organization to support …See details»
Xencor | Proteins By Design®
Xencor is expanding the therapeutic boundaries of antibody drugs. Powered by its XmAb ® protein engineering platform, Xencor is developing a broad pipeline of drug candidates that …See details»
Xencor - Crunchbase Company Profile & Funding
Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed …See details»
Investors | Xencor, Inc.
Mar 11, 2025 Investors have been drawn to Xencor’s remarkable scientific capabilities around protein engineering and our broad intellectual property, which serve as the engine behind our …See details»
Xencor - LinkedIn
Xencor | 9,707 followers on LinkedIn. Proteins by Design | Proteins by Design Antibody and protein biotherapeutics are changing the way physicians treat autoimmune diseases, asthma, and cancer. At ...See details»
Board of Directors | Xencor, Inc.
Dahiyat has more than 25 years of experience in the biotechnology business, having co-founded Xencor in 1997. From 1997 to 2003, he served as our Chief Executive Officer, and from 2003 …See details»
Xencor - The Org
Xencor develops superior monoclonal antibody therapeutics to treat autoimmune disorders, asthma, allergic diseases and cancer.See details»
Careers - Xencor
Or mail to Xencor: 111 W. Lemon Ave., Monrovia CA 91016. CONTACT US. info@xencor.com collaborate@xencor.com. Xencor Headquarters 465 North Halstead Street, Suite 200 …See details»
Xencor, Inc. Company Profile | Pasadena, CA - Dun & Bradstreet
Company Description: Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibodies and cytokine therapeutics to …See details»
Xencor Inc - AnnualReports.com
Xencor is a clinical stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Visit website. Social Media Links. REPORT …See details»
XENCOR INC Company Profile | San Diego, CA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for XENCOR INC of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Xencor Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Xencor has 5 employees across 2 locations and $110.5 m in annual revenue in FY 2024. See insights on Xencor including office locations, competitors, revenue, financials, …See details»
Xencor - Funding, Financials, Valuation & Investors - Crunchbase
Xencor is registered under the ticker NASDAQ:XNCR . Their stock opened with $5.50 in its Dec 6, 2013 IPO. Xencor is funded by 7 investors. Oxford Bioscience Partners and Novo Nordisk are …See details»
Xencor Overview | SignalHire Company Profile
To connect with Xencor employee register on SignalHire. Organization Website: xencor.com : Social Links: Phone Number: 626-305-5900: Xencor industries Biotech, Biotechnology: …See details»
Xencor - Contacts, Employees, Board Members, Advisors & Alumni …
Organization. Xencor . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 8. Number of Board …See details»
Xencor - Biocom California
Today, Xencor is revolutionizing antibody drug development with its XmAb protein engineering platform and has more than 20 programs in clinical testing in therapeutic areas ranging from …See details»
Xencor Inc Company Profile - Overview - GlobalData
Xencor's Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. …See details»
Annual Reports - Xencor, Inc.
Feb 28, 2018 Add Links to Pages. 2023 Annual Report. Feb 27, 2023See details»
A Brief History of Xencor – CanvasBusinessModel.com - CBM
Oct 2, 2024 Founding and Origins of Xencor. Xencor was founded in 1997 by Dr. Bassil Dahiyat and Dr. Stephen Mayo, two prominent scientists in the field of protein engineering. The company was established with the vision of developing innovative monoclonal antibody therapeutics to address unmet medical needs in autoimmune disorders, asthma, allergic diseases, and cancer.See details»
Xencor, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Xencor, Inc. with its drug pipeline, therapeutic area, technology platform, 33 clinical trials, 275 news, and 38 literature, Disease Domain:Neoplasms, Immune System Diseases, Hemic …See details»